Adaptive Biotechnologies Corporation

NasdaqGS:ADPT

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

💻 Telehealth

💉 Vaccines

Location

United States

Market Cap

USD 1.60 B

Share Price

USD 10.56

Avg Daily Volume

2,249,909

Change (1 day)

1.73%

Change (1 year)

225.93%

Change (YTD)

76.00%

Adaptive Biotechnologies Corporation Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2025: -71.50%

Adaptive Biotechnologies Corporation Operating Income Margin is -71.50% for the Trailing 12 Months (TTM) ending March 31, 2025, a -35.41% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Adaptive Biotechnologies Corporation Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was -110.70%, a 5.02% change year over year.
Adaptive Biotechnologies Corporation Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -105.41%, a -29.41% change year over year.
Adaptive Biotechnologies Corporation Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -149.33%, a 8.54% change year over year.
Adaptive Biotechnologies Corporation Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -137.58%, a 38.10% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Income Margin	Gross Profit Margin	EBIT Margin	EBITDA Margin

NasdaqGS: ADPT

Adaptive Biotechnologies Corporation

CEO	Mr. Chad M. Robins M.B.A.
IPO Date	June 27, 2019
Location	United States
Headquarters	1165 Eastlake Avenue East
Employees	619
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals 💻 Telehealth 💉 Vaccines

Description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.